Current options in antifungal pharmacotherapy - PubMed (original) (raw)
Review
Current options in antifungal pharmacotherapy
John Mohr et al. Pharmacotherapy. 2008 May.
Abstract
Infections caused by yeasts and molds continue to be associated with high rates of morbidity and mortality in both immunocompromised and immunocompetent patients. Many antifungal drugs have been developed over the past 15 years to aid in the management of these infections. However, treatment is still not optimal, as the epidemiology of the fungal infections continues to change and the available antifungal agents have varying toxicities and drug-interaction potential. Several investigational antifungal drugs, as well as nonantifungal drugs, show promise for the management of these infections.
Similar articles
- Management of invasive fungal infections: a role for polyenes.
Chandrasekar P. Chandrasekar P. J Antimicrob Chemother. 2011 Mar;66(3):457-65. doi: 10.1093/jac/dkq479. Epub 2010 Dec 14. J Antimicrob Chemother. 2011. PMID: 21172787 Review. - Antifungals in Clinical Use and the Pipeline.
Johnson MD. Johnson MD. Infect Dis Clin North Am. 2021 Jun;35(2):341-371. doi: 10.1016/j.idc.2021.03.005. Infect Dis Clin North Am. 2021. PMID: 34016281 Review. - The value of amphotericin B in the treatment of invasive fungal infections.
Klepser M. Klepser M. J Crit Care. 2011 Apr;26(2):225.e1-10. doi: 10.1016/j.jcrc.2010.08.005. Epub 2010 Oct 15. J Crit Care. 2011. PMID: 20951541 Review. - Recent approaches to antifungal therapy for invasive mycoses.
Mathew BP, Nath M. Mathew BP, et al. ChemMedChem. 2009 Mar;4(3):310-23. doi: 10.1002/cmdc.200800353. ChemMedChem. 2009. PMID: 19170067 Review. - [Antifungals for systemic use].
Ruiz-Camps I, Cuenca-Estrella M. Ruiz-Camps I, et al. Enferm Infecc Microbiol Clin. 2009 Jun;27(6):353-62. doi: 10.1016/j.eimc.2009.04.001. Epub 2009 May 31. Enferm Infecc Microbiol Clin. 2009. PMID: 19482382 Review. Spanish.
Cited by
- Natural products: a continuing source of novel drug leads.
Cragg GM, Newman DJ. Cragg GM, et al. Biochim Biophys Acta. 2013 Jun;1830(6):3670-95. doi: 10.1016/j.bbagen.2013.02.008. Epub 2013 Feb 18. Biochim Biophys Acta. 2013. PMID: 23428572 Free PMC article. Review. - An insight into new strategies to combat antifungal drug resistance.
Zheng YH, Ma YY, Ding Y, Chen XQ, Gao GX. Zheng YH, et al. Drug Des Devel Ther. 2018 Nov 5;12:3807-3816. doi: 10.2147/DDDT.S185833. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30464412 Free PMC article. Review. - Emerging Polymer-Based Nanosystem Strategies in the Delivery of Antifungal Drugs.
Xin Y, Quan L, Zhang H, Ao Q. Xin Y, et al. Pharmaceutics. 2023 Jul 1;15(7):1866. doi: 10.3390/pharmaceutics15071866. Pharmaceutics. 2023. PMID: 37514052 Free PMC article. Review. - Contribution of galactofuranose to the virulence of the opportunistic pathogen Aspergillus fumigatus.
Schmalhorst PS, Krappmann S, Vervecken W, Rohde M, Müller M, Braus GH, Contreras R, Braun A, Bakker H, Routier FH. Schmalhorst PS, et al. Eukaryot Cell. 2008 Aug;7(8):1268-77. doi: 10.1128/EC.00109-08. Epub 2008 Jun 13. Eukaryot Cell. 2008. PMID: 18552284 Free PMC article. - Triazole antifungal agents in invasive fungal infections: a comparative review.
Lass-Flörl C. Lass-Flörl C. Drugs. 2011 Dec 24;71(18):2405-19. doi: 10.2165/11596540-000000000-00000. Drugs. 2011. PMID: 22141384 Review.
Publication types
MeSH terms
Substances
Grants and funding
- K23 AI051537/AI/NIAID NIH HHS/United States
- K23 AI051537-01/AI/NIAID NIH HHS/United States
- L30 AI057128/AI/NIAID NIH HHS/United States
- L30 AI057128-01/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous